Evaluation of the Efficacy and Safety of APL-2 in Patients with
The purpose of this study is to evaluate long term safety and efficacy of ACH-0144471 in patients with PNH who have demonstrated clinical benefit from ACH-0144471 in Clinical Study ACH471-100. This study is designed to include up to 12 patients.
The primary purpose of this study is to evaluate the safety, tolerability, and efficacy of multiple intravenous (IV) doses of ravulizumab administered to complement inhibitor treatment-naïve participants with PNH.
This is a randomized, double-blind, active-controlled phase 3 study of ABP 959 in participants with
The primary purpose of this study was to assess the noninferiority of ravulizumab compared to